CHICAGO, July 24, 2019 (GLOBE NEWSWIRE) -- Tolmar Pharmaceuticals, Inc. today announced the publication of a study of nadir testosterone (T) levels achieved in pivotal trials for ELIGARD ® (leuprolide ...
More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the ...
Please provide your email address to receive an email when new articles are posted on . Relugolix demonstrated superiority over leuprolide acetate in sustained testosterone suppression through 48 ...
Combined mTOR and AKT inhibition in renal cell carcinoma (RCC). Background: Leuprolide acetate is a synthetic analog of gonadotropin hormone-releasing hormone (GnRH-a) that reduces serum testosterone ...
More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a new article.
Injectable luteinizing hormone–releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and ...
*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback